Findings report on ability to measure cellular and soluble inflammatory protein biomarkers in sputum, including biologic drug targets
Company advances research and development in diagnostic tests for major lung diseases building on CyPath® Lung + AI foundation
Global asthma therapeutics market projected to reach $47.6 billion by 2034
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)),a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced it will present new data at CHEST 2026, the annual meeting of the American College of Chest Physicians, on the Company's sputum-based tests in development to characterize lung inflammation and detect multiple protein biomarkers of lung inflammation, including biologic drug targets of therapeutics used to treat asthma and chronic obstructive pulmonary disease (COPD).
By providing a more complete picture of a patient's inflammatory profile, this research approach may, with further development and validation, help inform identification of patients who could benefit from specific biologic therapies and support monitoring of lung inflammation over time, consistent with a precision medicine approach.
bioAffinity Technologies will present a poster, titled "Sputum as a Diagnostic Tool for the Measurement of Lung Inflammation in Asthma," that describes a workflow based on the proprietary flow cytometry + AI platform used by the Company's commercially available noninvasive CyPath® Lung diagnostic for lung cancer.